MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461617 | Name: Bitolterol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bitolterol is a new beta 2-adrenergic agonist and classified as a pro-drug.

Chemical Structure

Bitolterol
Bitolterol
CAS#30392-40-6 (free base)

Theoretical Analysis

MedKoo Cat#: 461617

Name: Bitolterol

CAS#: 30392-40-6 (free base)

Chemical Formula: C28H31NO5

Exact Mass: 461.2202

Molecular Weight: 461.55

Elemental Analysis: C, 72.86; H, 6.77; N, 3.03; O, 17.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
30392-40-6 (free base) 30392-41-7 (mesylate) 912649-33-3 (R-isomer)
Synonym
Bitolterol; Bitolterolum; S 1540; S-1540; S1540; Win 32,784; Win32784; Win 32784; Win-32784; Tornalate; Effectin;
IUPAC/Chemical Name
4-(2-(tert-butylamino)-1-hydroxyethyl)-1,2-phenylene bis(4-methylbenzoate)
InChi Key
FZGVEKPRDOIXJY-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3
SMILES Code
OC(C1=CC=C(OC(C2=CC=C(C)C=C2)=O)C(OC(C3=CC=C(C)C=C3)=O)=C1)CNC(C)(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 461.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pinnas JL, Bernstein IL, Bronsky EE, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Nathan RA, Repsher LH, Bhatt BD, et al. Multicenter study of bitolterol and isoproterenol nebulizer solutions in nonsteroid-using patients. J Allergy Clin Immunol. 1987 May;79(5):768-75. PubMed PMID: 3571768. 2: Walker SB, Kradjan WA, Bierman CW. Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. Review. PubMed PMID: 3895171. 3: Nathan RA, Bodman SF, Storms WW, Mingo TS. Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol hydrochloride aerosol. Ann Allergy. 1986 Jun;56(6):494-9. PubMed PMID: 3717716. 4: Bierman CW, Kemp JP, Nathan RA. Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol. 1996 Jan;76(1):27-35. PubMed PMID: 8564625. 5: Petty TL, Scoggin CH, Rollins DR, Repsher LH. Bitolterol compared to isoproterenol in advanced chronic obstructive pulmonary disease. Chest. 1984 Sep;86(3):404-8. PubMed PMID: 6380974. 6: Nathan RA, Bernstein IL, Bronsky EA, Bush RK, Chervinsky P, Condemi JJ, Dockhorn RJ, Pinnas JL, Repsher LH. Comparison of the bronchodilator effects of nebulized bitolterol mesylate and isoproterenol hydrochloride in steroid-dependent asthma. J Allergy Clin Immunol. 1987 May;79(5):822-9. PubMed PMID: 3571773. 7: Friedel HA, Brogden RN. Bitolterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible obstructive airways disease. Drugs. 1988 Jan;35(1):22-41. Review. PubMed PMID: 3278878. 8: Walker SB, Bierman CW, Pierson WE, Shapiro GG, Furukawa CT, Mingo TS. Bitolterol mesylate in exercise-induced asthma. J Allergy Clin Immunol. 1986 Jan;77(1 Pt 1):32-6. PubMed PMID: 3944373. 9: Kemp JP, Pinnas JL, Tinkelman DG, Meltzer EO, Campbell SC, Orgel HA, Welch MJ, Mingo TS. Comparison of bronchodilator responses with bitolterol mesylate solution with the use of two different nebulizer systems in asthma. J Allergy Clin Immunol. 1986 Mar;77(3):509-15. PubMed PMID: 3950254. 10: Orgel HA, Kemp JP, Tinkelman DG, Webb DR Jr. Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta 2-adrenergic bronchodilators for treatment of asthma. J Allergy Clin Immunol. 1985 Jan;75(1 Pt 1):55-62. PubMed PMID: 3968329. 11: Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP. Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma. Ann Allergy. 1994 Mar;72(3):209-16. PubMed PMID: 8129213. 12: Hunke WA, Yu AB. Particle-size distribution of bitolterol mesylate solution delivered by four compressed-air nebulizer devices. Am J Hosp Pharm. 1987 Jun;44(6):1392-6. PubMed PMID: 3618619. 13: Nakanishi H, Nakahata N, Ito G, Yoshida H. Comparative heart rate effects of oral administration of bitolterol, terbutaline and trimetoquinol in unanesthetized dogs. Res Commun Chem Pathol Pharmacol. 1980 Apr;28(1):185-8. PubMed PMID: 6104851. 14: Minatoya H. Studies on bitolterol, di-p-toluate ester of N-tert.-butylarterenol: a new long-acting bronchodilator with reduced cardiovascular effects. J Pharmacol Exp Ther. 1978 Sep;206(3):515-27. PubMed PMID: 702319. 15: Kemp JP, Chervinsky P, Orgel HA, Meltzer EO, Noyes JH, Mingo TS. Concomitant bitolterol mesylate aerosol and theophylline for asthma therapy, with 24 hr electrocardiographic monitoring. J Allergy Clin Immunol. 1984 Jan;73(1 Pt 1):32-43. PubMed PMID: 6693665. 16: Harris JB, Ahrens RC, Milavetz G, Annis L, Ries R, Hendricker C. Comparison of the intensity and duration of effects of inhaled bitolterol and albuterol on airway caliber and airway responsiveness to histamine. J Allergy Clin Immunol. 1990 Jun;85(6):1043-9. PubMed PMID: 2191990. 17: Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG. Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients. Chest. 1987 Apr;91(4):533-9. PubMed PMID: 3549173. 18: Shargel L, Dorrbecker SA, Levitt M. Physiological disposition and metabolism of N-t-butylarterenol and its di-p-toluate ester (bitolterol) in the rat. Drug Metab Dispos. 1976 Jan-Feb;4(1):65-71. PubMed PMID: 3403. 19: Aimoto T, Ito O, Kimura R, Murata T, Ito K. The influences of the route of administration on the metabolism and excretion of bitolterol, a new bronchodilator, in the rat. Xenobiotica. 1979 Mar;9(3):173-80. PubMed PMID: 473792. 20: Messina MS. Retrospective study of bitolterol mesylate in the treatment of conditions associated with reversible bronchospasm. Adv Ther. 1995 May-Jun;12(3):157-63. PubMed PMID: 10155050.

View History

Pifithrin-alpha

Pifithrin-alpha

New Featured